Interview with Jürgen Dormann: Will Aventis Sell the Farm?
Investors blast the drug maker for hanging on to its low-margin agricultural business. But Allegra, its hot new antiallergy drug, could rack up $1 billion in sales this year.
David Lanchner
July 1, 2000